Your session is about to expire
← Back to Search
NMDA Receptor Antagonist
Low-Dose Ketamine (LDK) Treatment Group for Endometriosis
Phase 1
Recruiting
Led By Kathy Huang, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Scheduled to undergo robotic endometriosis removal surgery
Adults, aged 18 to 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative day (pod) 83
Awards & highlights
Study Summary
This trial will study whether a low dose of ketamine can help relieve postoperative pain and recovery in women with chronic pelvic pain who are undergoing robotic removal of endometriosis.
Who is the study for?
This trial is for adult women aged 18-65 with chronic pelvic pain who are scheduled for robotic endometriosis removal surgery. Participants should be medically stable and willing to follow the study procedures throughout its duration.Check my eligibility
What is being tested?
The UPKEEP Study tests if a low dose of ketamine (0.6 mg/kg) can better manage postoperative pain compared to a saline placebo in female patients after robotic endometriosis surgery. It's randomized and single-blinded, meaning participants won't know which treatment they receive.See study design
What are the potential side effects?
Ketamine may cause side effects such as feelings of disconnection from reality, changes in perception, nausea, dizziness, mood swings, or blurred vision. The severity varies among individuals.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for a robotic surgery to remove endometriosis.
Select...
I am between 18 and 65 years old.
Select...
I have had moderate to severe pelvic pain for more than 6 months.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ post-operative day (pod) 83
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-operative day (pod) 83
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pelvic Pain Score on Visual Analogue Scale (VAS)
Secondary outcome measures
Change in Opioid Use
Score on Endometriosis Health Profile-30 (EHP-30) Questionnaire
Score on General Anxiety Disorder-7 Screener (GAD-7)
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Low-Dose Ketamine (LDK) Treatment GroupExperimental Treatment1 Intervention
Group II: Control GroupPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,372 Previous Clinical Trials
841,080 Total Patients Enrolled
Kathy Huang, MDPrincipal InvestigatorNYU Langone Health
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
How old are they?
18 - 65
What site did they apply to?
NYU Langone Health
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Share this study with friends
Copy Link
Messenger